Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life

Novartis AG NVS is building the case for its radioligand therapy, 177Lu-PSMA-617.
With positive Phase 3 primary endpoint data in the bag, Novartis at the European Society of Medical Oncology Congress 2021 (ESMO21) presented the therapy's effect on the quality of life and pain.
Earlier this year, Novartis revealed that the Phase 3 trial linked 177Lu-PSMA-617 to a four-month median improvement in overall survival.
Related Link: Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months.
Novartis sought to understand the effect of 177Lu-PSMA-617 on daily activities through secondary endpoints that looked at the patient-reported quality of life and pain.
The endpoints linked the drug to estimated risk reductions in the worsening of health-related quality of life and pain intensity of 54% and 55%, respectively.
Read Next: Novartis Beefs Up Radioligand Portfolio With iTheranostics Deal.
The company is ramping up other studies that could enable it to bring 177Lu-PSMA-617 to more prostate cancer patients.
In one study, Novartis is enrolling men who are yet to take taxanes, a class of chemotherapy drugs.
The other ongoing trial could move 177Lu-PSMA-617 into an even line of treatment by testing it in combination with standard of care.
Price Action: NVS stock closed 0.82% lower at $84.38 on Thursday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).